**METHODS.**

The present study is reported in alignment to the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement [cite]. Perhaps it should even be the RECORD-PE statement (for pharmacoepiemiology)?

**Study design.** Simulated trial using ABC trial arm data in combination with a synthetic arm derived from a retrospective longitudinal real-world data.

**Setting.** We herein analysed EHRs detailing the provision of ophthalmologic care across 27 sites within England, the United Kingdom during year–year. All EHRs were recorded using the Medisoft Ophthalmology platform (<http://www.medisoft.co.uk>). ABC trial.

**Participants.**

***ABC trial arm (Avastin).*** Summary. Avastin treatment regigment.

***Synthetic control arm (Eylea).*** Describe Medisoft dataset.

The synthetic control arm consisted of eyes (excluding contralaterally affected) being treated with Eylea (dose/frequency) as per standard care for indications of age-related macular degeneration. In alignment with the ABC trial, we excluded eyes that underwent or received or developed before baseline (unless stated otherwise): I) stereotactic radiotherapy, transpupillary thermo therapy, or photodynamic therapy (thermal laser unrecorded); II) photodynamic therapy—as a proxy for verteporfin administration—in the contralateral eye within seven days of baseline; III) Macugen, Avastin, or Lucentis; IV) intravitreal Dexamatheasone, Triesence or other implantation; V) vitrectomy; VI) diabetic retinopathy akin to an NSC grade of ≥ R1 or M1; VII) trabeculectomy; VIII) keratoplasty; or IX) any submacular surgery for AMD. In addition to the ABC eligibility, we also excluded all eyes that switched to Avastin or Lucentis during the study period and—pertinent to PS—all eyes that had missing gender, age, and baseline visual acuity.

From this pool of eyes aligned with the ABC trial criteria we matched

propensity score matching/inverse propbability weighting.

**Variables.**

**Data sources/measurement.**

**Bias.**

**Study size.**

Calculate statistical power (likelihood of overlooking an association) given sample size.

**Quantitative variables.**

**Statistical methods.**

Outstanding questions.

How many boostrap iterations?

Bootstrap with or without replacement across iterations?

Boostrap with or without replacement within iteration?

**Data access and cleaning methods.**

**Linkage.**